FDA Approves First Epoetin Alfa Biosimilar for Anemia Treatment
May 16th 2018The FDA today approved epoetin alfa-epbx (Retacrit) as a biosimilar to epoetin alfa (Epogen/Procrit) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection
Read More
FDA Approves Treatment for Active Polyarticular Juvenile Idiopathic Arthritis
May 15th 2018Officials with the FDA announced the approval subcutaneous formulation of tocilizumab (Actemra) for treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.
Read More